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Detailed resource utilization data were collected for all patients from 8 countries 
(U.S.,Australia,Canada,Germany,Italy,Spain,UK and France; n  3373 prasugrel, n  
3332 clopidogrel). Hospitalization costs were estimated from the perspective of the 
German health care system on the basis of diagnosis-related groups (DRGs) for 
Germany and in-hospital complications. Costs for cardiovascular medications were 
estimated using public price per tablet (clopidogrel  a2.68/day; prasugrel  a2.94/
day). Life expectancy (LE) was estimated based on in-trial cardiovascular and bleeding 
events, using statistical models developed from a similar population from the Saskatch-
ewan Health Database. Costs in added years of life were not included in the base case. 
The analysis was carried out for the overall cohort and the 10 mg. recommended 
population of patients with no history of stroke/TIA, age  75 and body wt. 60kg. 
RESULTS: Over a median 14.5 month follow-up period, average total costs were 
a15/patient (a20/patient for the 10 mg. recommended population) lower with prasu-
grel, due to a lower rate of rehospitalization involving PCI. Prasugrel was associated 
with LE gains of 0.102 years (0.129 for the 10 mg. recommended population), due 
primarily to the decreased rate of non-fatal MI. Compared to clopidogrel, prasugrel 
was thus an economically dominant treatment strategy. When compared to generic 
clopidogrel at a cost of  a1.80/day, there was an incremental net cost with prasugrel 
of a281/patient (a285/patient for the 10 mg. recommended population), and an ICER 
of a2743/life year gained (a2213/life year gained for the 10 mg. recommended popula-
tion). CONCLUSIONS: For ACS patients with planned PCI, prasugrel for up to 15 
months compared with current standard of care is an economically attractive treat-
ment strategy.
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THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT 
OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND
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OBJECTIVES: Ambrisentan, a non-sulphonamide endothelin receptor antagonist 
(ERA) was recently licensed for the treatment of Pulmonary Arterial Hypertension 
(PAH). The study objective was to estimate the cost-effectiveness of ambrisentan from 
an Irish Healthcare perspective. METHODS: A discrete event simulation model devel-
oped by United BioSource Corporation was used to compare the cost-effectiveness of 
ambrisentan relative to two other ERAs (bosentan, sitaxentan) over a ﬁve year time 
horizon. The probability of clinical worsening and liver abnormality events were pre-
dicted from regression equations derived from the ambrisentan clinical trials data. 
These regression equations were also used to predict events for the comparator thera-
pies by calibrating them to reproduce treatment effects consistent with those reported 
in the literature. Costs and utilities were then assigned to these events and were dis-
counted at 3.5%. Costs were obtained from Irish speciﬁc and UK sources and were 
in 2007 prices. Utility values were derived from ambrisentan clinical trials. RESULTS: 
It was estimated that ambrisentan is cost saving with improved health outcomes 
compared to both bosentan and sitaxentan; ambrisentan dominated both bosentan 
(a195,788/QALY) and sitaxentan (a138,780/QALY). This result was driven by the 
higher incidence of liver abnormalities associated with bosentan and sitaxentan com-
pared to ambrisentan. When patients experienced liver abnormalities a proportion of 
them switched to prostacylin therapy, which was more expensive and associated with 
lower QALYs than ERA therapy. Probabilistic sensitivity analysis revealed that the 
likelihood of ambrisentan dominating bosentan and sitaxentan was 86% and 73%, 
respectively. CONCLUSIONS: Ambrisentan is a cost-effective alternative for the treat-
ment of PAH in Ireland. This is because it results in a lower incidence of liver abnor-
malities compared to existing ERAs.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percu-
taneous coronary intervention (PCI), the TRITON-TIMI 38 trial (TTT) demonstrated 
that treatment with prasugrel vs. clopidogrel signiﬁcantly reduced rates of athero-
thrombotic events, though with increased risk of bleeding. We evaluated the long-term 
cost-effectiveness of this approach in patients free of stroke or TIA, from the perspec-
tive of the UK National Health Service. METHODS: A Markov model was developed 
based on risk equations for cardiovascular death, myocardial infarction (MI) or stroke, 
bleeding, and rehospitalisation, derived from TTT (N  13,608 patients). Hospital 
readmissions captured during the trial in all patients from 8 countries (N  6,705) 
were assigned to UK diagnosis related groups. After 12 months, common rehospitali-
sation costs were modelled to accrue over the life-time time horizon. RESULTS: 
During the ﬁrst year incremental drug cost of prasugrel (£162/patient) was partially 
offset by hospital cost savings (£14/patient) due principally to reduced revasculariza-
tion rates. Over the longer-term, prasugrel was associated with higher total costs 
resulting from rehospitalisations among survivors, of £169/patient, with life expec-
tancy gains of 0.06 years primarily due to reduced rate of MI, and 0.05 additional 
QALYs. Incremental cost per life year gained and per QALY gained were £2,606 and 
£3435 respectively. These results were consistent across subgroups, with incremental 
costs per QALY gained of £4494 in UA/NSTEMI, £2167 in STEMI, and £3461 in 
patients without any of three risk factors for bleeding (prior TIA/stroke, weight  
60kg, age q 75 years). Probabilistic sensitivity analysis indicated a 72% probability         
of prasugrel being cost-effective compared with branded clopidogrel at a willingness 
to pay of £20,000 per QALY. CONCLUSIONS: Prasugrel treatment to 1 year in 
ACS-PCI patients appears cost-effective compared with branded clopidogrel.
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OBJECTIVES: Literature shows that patients admitted to the intensive care unit (ICU) 
after cardiopulmonary resuscitation (CPR) have a worse clinical and economic 
outcome in terms of increased length of stay (LOS) in the ICU and a high mortality. 
In this study we investigated survival, health-related quality of life (HRQOL), costs 
and cost-effectiveness of patients admitted to the ICU after CPR. METHODS: A pro-
spective observational cohort analysis was performed. In the period of March 3– 
November 3, 2008, all consecutive patients admitted to the ICU after CPR necessitating 
mechanical ventilation were screened for inclusion. All data concerning demography, 
comorbidity, severity of disease, organ failure, ICU and hospital LOS were analyzed. 
Data concerning costs were restricted to hospital-related costs and further to direct 
costs. HRQOL before admission and 3 months after ICU-discharge was assessed using 
standardized questionnaires (EuroQoL 5D, Short Form-36 scores). Statistical signiﬁ-
cance was attained at P  0.05. RESULTS: Out of 39 patients admitted because of 
CPR, 35 patients (66% males) with a mean age of 62 years (SD 14.6) and APACHE 
II-score of 26.9 (SD 9) were included. Mortality was 57%. The 15 patients that 
survived had an equal HRQOL before and after ICU-discharge concerning pain 
(P  0.6), general health (P  0.2), vitality (P  0.1), role-emotional (P  0.1) and 
mental health (P  0.9). HRQOL was diminished on physical functioning (P  0.01), 
role-physical (P  0.007) and social functioning (P  0.02). Costs per hospital survivor 
were a92,139, and a6,399/quality adjusted life year (QALY). A sensitivity-analysis 
conﬁrmed the cost-effectiveness of ICU treatment after CPR. CONCLUSIONS: 
Mortality after CPR was high and comparable with data from literature. After 
three months, HRQOL was only worse when looking at physical level. Treatment 
after CPR necessitating mechanical ventilation was found to be a cost-effective 
intervention.
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OBJECTIVES: ExTRACT-TIMI 25 is a prospective randomized trial of 20,479 
patients with 1,279 recruited in Spain. The use of enoxaparin as adjunctive therapy 
for ﬁbrinolysis in patients with ST-segment elevation myocardial infarction versus 
unfractionated heparin (UFH) resulted in a 17% relative risk reduction of death or 
non-fatal myocardial infarction (MI). Using results from the ExTRACT-TIMI 25 trial 
we conducted an economic evaluation to estimate the cost-effectiveness of enoxaparin 
in Spain. METHODS: Cost-effectiveness analysis was performed from the Spanish 
National Health Service perspective. Health resource data were obtained from the 
ExTRACT-TIMI 25 trial, coding according to Diagnostic Related Groups (DRGs). 
Medical direct costs data (procedures and drugs) were obtained from published 
Spanish literature. Survival and life expectancy were estimated from the Framingham 
Heart Study. Results are presented as incremental cost per life year gained (LYG) and 
cost per Quality Adjusted Life Years (QALY). To prove the robustness of the results 
we calculated 95% conﬁdence intervals for both costs and results. Long-term costs 
were discounted at 3% annually after the ﬁrst year. RESULTS: Considering short-term 
treatment results (30 days), enoxaparin achieved better results with more LYG than 
UFH but there was a not signiﬁcant difference in total costs. The incremental cost-
effectiveness ratio for enoxaparin obtained from the 30 days analysis was a977.5/
LYG. When long-term (lifelong) analysis was performed the cost obtained was of 
a2755.6/LYG and a3442.3/QALY. CONCLUSIONS: Considering the usual “willing-
ness to pay” cost-effectiveness threshold in Spain (a30,000 per LYG and per QALY) 
enoxaparin administered as adjunctive therapy for ﬁbrinolysis in ST-elevation myo-      
cardial infarction patients is a potentially cost-effective strategy compared with UFH 
in Spain.
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OBJECTIVES: Exercise training is an effective strategy to reduce combined clinical 
outcomes in heart failure (HF). Nonetheless, implementation of such programs 
has been restricted to university and specialized centers. Economic analysis of this 
A330 Paris Abstracts
intervention may help reinforce health policy worldwide. METHODS: Using a 
Markov model, we performed a cost-effectiveness analysis to estimate the costs, health 
gains, and incremental cost-effectiveness (international dollars [I$] per quality-adjusted 
life year [QALY] gained) of an exercise training program in HF class II and III NYHA 
patients, comparing with standard treatment, assuming a public system perspective in 
Brazil. QALYs were estimated from an outpatient cohort of 318 patients. Treatment 
efﬁcacy was obtained from controlled trials and meta-analysis; treatment costs were 
derived from published data and National Health System reimbursement rates in 
2008. Exercise training costs were obtained from a cardiac rehabilitation center. 
Robusteness of results was tested by Monte Carlo simulation and sensitivity analysis. 
RESULTS: Considering a 35% reduction of mortality with exercise training and an 
annual cost of I$ 1,176 per patient, this strategy had a total cumulative cost of I$ 
25,856 and 4.95 QALYs. Comparing with standard treatment, which had a total cost 
of I$ 16,758 and 4.34 QALYs, the incremental cost per QALY of exercise training 
was I$ 14,965. Results were sensitive to intervention-related costs and effect size. 
Considering the results of the HF-ACTION trial, in a time-limited exercise program 
with a 11% combined event (all-cause mortality or hospitalization) reduction and an 
exercise cost of I$ 470 per patient, incremental cost-effectiveness ratio would be I$ 
19,828/QALY. CONCLUSIONS: Under several assumptions, exercise training 
appeared to be cost-effective, and to offer good value for money compared to other 
well-accepted HF treatment strategies. The results support implementing such inter-
vention as part of public health efforts to improve HF management.
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OBJECTIVES: In the INFORCE study, treatment with ezetimibe/simvastatin (Eze/
Simva) 10/40 mg/day was superior to doubling the statin dose in reducing total cho-
lesterol (TC) among inpatients with suspected coronary events already receiving a 
statin (stratiﬁed into 3 potency strata at baseline). The purpose of this analysis was 
to evaluate the cost-effectiveness of Eze/Simva in this population by translating reduc-
tions in the observed TC: high-density lipoprotein cholesterol ratio into projected 
lifetime costs and beneﬁts. METHODS: A Markov model (Cook et al 2004) was used 
to project lifetime costs and beneﬁts based on patients’ cardiovascular risk factor 
proﬁles and actual lipid values at baseline and endpoint (12 weeks). Inputs for car-
diovascular event costs and age-speciﬁc utilities for health states were based on a 2006 
National Institute of Health and Clinical Excellence submission for Eze and age-spe-
ciﬁc non–CHD mortality rates (2006) derived from UK Ofﬁce of National Statistics 
mortality data. RESULTS: At baseline, the Eze/Simva group (N  195) had a higher 
mean [SD] TC (4.33 [0.89] mmol/L) than the double-statin group (N  189; 4.16 
[0.80] mmol/L). In the pooled-data analysis adjusted for baseline proﬁle, Eze/Simva 
conferred 0.218 discounted (3.5%) incremental quality-adjusted life year (QALY) at 
a discounted (3.5%) incremental cost of £2,524, for an Incremental Cost-Effectiveness 
Ratio (ICER) of £11,571/QALY. Similar data were observed in each stratum of statin 
LDL-C–lowering potency, with ICER values £15,000/QALY for each comparison 
of Eze/Simva to statins: Eze/Simva was cost-effective in the low-potency (£13,552/
QALY), medium-potency (£11,930/QALY), and high-potency (£10,148/QALY) statin 
strata in adjusted analyses. On bootstrapping analysis, the ICER for Eze/Simva therapy 
was £20,000/QALY in 99% of replicates for the adjusted analysis. CONCLUSIONS: 
Among UK inpatients evaluated for coronary events, switching to Eze/Simva 10/40 mg 
is projected to be a cost-effective treatment alternative (vs doubling the statin dose) 
based on a commonly applied UK ICER threshold (£20,000–£30,000).
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OBJECTIVES: Statin dose escalation to reach low-density lipoprotein cholesterol 
(LDL-C) goals is an established practice. This study analyzes the health economic 
impact of titrating patients to a target LDL-C of 100 mg/dl as recommended by current 
guidelines. First-line brand rosuvastatin and ﬁrst-line generic simvastatin protocols are 
compared. METHODS: A published state-transition model was used, linking age, 
smoking status, systolic blood pressure, and total cholesterol (TC) to fatal CVD risk 
using the Belgian SCORE (primary prevention) and Framingham (secondary preven-
tion) equations. Non-fatal risk was based on landmark prevention trials. Patient 
LDL-C levels (mean/SD, before/after treatment start) were based on the STELLAR 
trial for simvastatin 20/40/80 mg and rosuvastatin 10/20/40 mg. Hence, consistent 
with the STELLAR trial a baseline LDL-C value (mg/dl) of (mean / SD) 189 / 19 
was applied. Other patient data were based on the DISCOVERY-BELUX trial that 
included Belgian patients. Resource use and unit costs were based on literature and 
ofﬁcial reimbursement tariffs. Patient groups starting on either rosuvastatin (10 mg) 
or simvastatin (20 mg) were compared. Patients not reaching LDL-C target were 
switched to the next higher dose of the same statin. Simvastatin 80 mg patients not 
reaching target were switched to 20 mg and if needed 40 mg of rosuvastatin. Cost-
effectiveness results were reported as EUR 2009 (direct medical costs from a public 
payer perspective) per Life Year gained (LYg) for a time horizon of 20 years. 
RESULTS: EUR/LYg values of 56,481 and 43,884 were found for respectively primary 
and secondary settings, well below some of the ICER values reported for other health 
care interventions attracting public reimbursement. Model explorations indicated that 
cost-effectiveness improved for lower LDL-C targets and higher baseline patient LDL-
C levels. CONCLUSIONS: Exclusive titration by rosuvastatin compared to starting 
patients ﬁrst on simvastatin, is likely to be cost-effective in patients with elevated 
LDL-C levels both in primary and secondary prevention.
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OBJECTIVES: This study aims to verify the economic feasibility of clopidogrelaspirin 
combination therapy by comparing the reduction in ischemic heart disease develop-
ment, and corresponding costs of aspirin monotherapy and clopidogrelaspirin com-
bination therapy (CT) in Korean acute coronary syndrome (ACS) patients. METHODS: 
We conducted a cost-effectiveness analysis of 3-years clopidogrelaspirin CT in ACS 
patients from a social perspective, taking into account all direct medical costs, direct 
non-medical costs, and indirect costs that occur during the course of clopidogrelaspirin 
CT and compared this to aspirin monotherapy. The effect of clopidogrel addition was 
applied, based on data from the Clopidogrel in Unstable angina to prevent Recurrent 
ischemic Events (CURE) study. The transition probability of Markov model was esti-
mated using health insurance claim data and records in the Korean Cause of Death 
Registry for the years 2001–2003. RESULTS: The long-term Markov model analysis 
revealed that the effect of clopidogrelaspirin CT compared with aspirin monotherapy 
in ACS patients was 0.207 life-years gained (LYG) and that the incremental cost-
effectiveness ratio analyzed as incremental costs per LYG was US$ 5,154.07. In addi-
tion, sensitivity analysis demonstrated that the relative risk and discount rate for 
cardiovascular events (acute myocardial infarction, stroke and cardiovascular death) 
were the variables that mainly affected the study results. CONCLUSIONS: A 38-year 
follow-up study of the 3-years effect of clopidogrelaspirin CT in Korea reveals that 
clopidogrel CT is a cost-effective alternative to aspirin monotherapy. Additionally, 
these results provide an economic justiﬁcation for recommending clopidogrel CT in 
the treatment of ACS patients within the Korean context.
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OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁable cardiovascular risk factor. Ivabradine is a speciﬁc HR lowering agent 
indicated in chronic stable angina (SA) patients with normal sinus rhythm, contrain-
dicated or intolerant to beta-blockers. This study aimed to estimate the cost-effective-
ness of ivabradine versus generic amlodipine in such patients, from the Finnish societal 
perspective. METHODS: A Markov chain Monte Carlo stochastic simulation model 
was used to estimate the inﬂuence of HR lowering in cardiovascular morbidity and 
mortality and its economic consequences. Ivabradine, 7.5 mg twice a day, was com-
pared against amlodipine, 10 mg once a day. HR distribution was modelled as a 
gamma function and survival and time to hospitalization were modelled with weibull 
functions. Only patients with resting HR       70 bpm were included. Events considered      
were acute myocardial infarction, stroke, heart failure and death, as well as revascu-
larization procedures (coronary artery bypass graft and percutaneous coronary inter-
ventions). Finnish setting was considered, including only direct costs, derived from the 
2006 Finnish Guidelines for Healthcare Unit Costs. Effectiveness was measured in life      
years (LY) and quality-adjusted life years (QALY). Time horizon was set at 20 years 
and discount rate was 5%/year for costs and effectiveness. RESULTS: For each 100 
patients using ivabradine in comparison with amlodipine we estimate a 36 LYs 
(95%CI: [18;57]) or 30 QALYs (95%CI: [17;47]) gain. Annual incremental cost per 
patient was a226 (95%CI: [201;243]). Incremental cost-effectiveness ratios for ivabra-
dine utilization were a12,886/LY and a15,060/QALY. For high levels of certainty     
(90%), willingness to pay for ivabradine’s beneﬁts didn’t exceed a24,000, regardless 
of the effectiveness measure considered. CONCLUSIONS: Ivabradine is a cost-
 effective alternative for the treatment of SA when compared to generic amlodipine     
in a Finnish setting of patients with contraindication or intolerance to beta-blockers         
and resting HR  70 bpm. 
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OBJECTIVES: High resting heart rate (HR) has been increasingly accepted as a 
modiﬁable cardiovascular risk-factor. Ivabradine has shown speciﬁc HR lowering 
properties and is indicated in chronic stable angina (SA) patients with normal sinus 
rhythm having a contraindication or intolerance for beta-blockers. The aim of this 
